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Abstract--Inasmuch as the recruitment of polymorphonuclear leukocytes (PMNs) to 
inflammatory foci in vivo involves adhesion-dependent events (e~g., margination, 
diapedesis, and directed migration), we sought to characterize the relationship 
between the local accumulation of PMNs in sterile peritonitis and their surface 
expression of the adhesion-promoting plasma membrane glycopmtein, Mol (CD1 lb/ 
CD18). In an immunofluorescence analysis of PMNs isolated from rats injected 
intraperitoneally with sterile 1% glycogen solution, we detected a significant 
enhancement of surface Mol expression by exudative peritoneal PMNs. In contrast, 
no significant rise in Mol expression was noted over time by circulating intravas- 
cular PMNs (isolated simultaneously). However, these intravascular PMNs had the 
capacity to increase their surface Mol density upon exposure to peritoneal fluid 
supernatant at 37~ These results demonstrate that PMNs at sites of inflammation 
in vivo do up-modulate their surface expression of the adhesion-promoting Mol 
glycoprotein during their recruitment from the circulating, intravascular leukocyte 
pool. 
I N T R O D U C T I O N  
The  recru i tment  o f  p o l y m o r p h o n u c l e a r  leukocytes  (PMNs)  f rom the intravas-  
cular  compar tmen t  to ex tmvascu la r  sites o f  in f lammat ion  is a characteris t ic  fea- 
ture o f  the acute  in f lammatory  response  ( rev iewed  in 1, 2). This  accumula t ion  
o f  P M N s  in v ivo ,  s t imulated by soluble  chemotac t ic  factors (1-3) ,  appears to 
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be accompanied by several cellular activation events including degranulation 
(4, 5) and alterations in cellular responsiveness to stimulated superoxide pro- 
duction (5, 6), membrane depolarization (5), and chemotaxis (5, 7-9). When 
enhanced, these effects may in part be due to the up-modulation of surface 
FMLP receptor expression (5). Another PMN activation event of particular 
interest in the inflammatory response is the up-modulation of cell surface Mol 
receptor density. Mol (CDllb/CD18) is a leukocyte plasma membrane gly- 
coprotein that promotes PMN adhesive functions, as demonstrated in vitro by 
the use of specific inhibitory routine anti-Mo 1 monoclonal antibodies (reviewed 
in 10), and by the recognition of an inherited disorder in which PMNs from 
affected persons are deficient in Mol expression and exhibit markedly impaired 
cellular adhesive functions (reviewed in 10, 11). PMN surface Mol expression, 
in concert with various cellular adhesive properties, is enhanced in vitro in 
response to exposure to soluble activating factors, including FMLP (12, 13), 
C5a (14-16), LTB4 (17, 18), adenine nucleotides (19), PMA, and calcium ion- 
ophore A23187 (12, 20, 21), and others. While it has been suggested that PMN 
Mol receptor up-modulation may occur in vivo (5, 14, 22-24), little is known 
about how this up-modulation might relate to the kinetics of PMN recruitment 
during inflammation. 
Therefore, we undertook this study of an animal model of sterile peritonitis 
to more fully characterize the PMN response to localized acute inflammation, 
as manifested by the surface expression of the Mol glycoprotein. The results 
herein demonstrate that there is a rapid, significant, and sustained up-modula- 
tion of surface Mol glycoprotein, which accompanies the accumulation of 
PMNs at sites of inflammation in vivo, lending further support to the notion 
that PMNs undergo cellular activation during inflammatory recruitment. 
MATERIALS AND METHODS 
Reagents. The following reagents were purchased from Sigma Chemical Company (St. 
Louis, Missouri): ammonium chloride (NH4C1, A4514), disodium ethylene-diaminetetraacetate 
(EDTA, ED2SS), and glycogen type II (derived from oyster, G8751). Sodium bicarbonate 
(NaHCO3, 15421) was obtained from Columbus Chemical Industries, Inc. (Columbus, Wisconsin). 
Fluoreseein isotbiocyanate-conjugated goat anti-mouse IgG -t- IgM antibodies were obtained from 
Tago, Inc. (6253, Burlingame, CA). 
Solutions. Phosphate-buffered saline (PBS, without calcium or magnesium) and Dulbecco's 
PBS (DPBS) were mixed according to standard formulations using reagent grade chemicals. NH4CI 
erythrocyte lysis buffer consisted of Nt-I4C10. t5 M, NaHCO3 0.01 M, and EDTA 0.001 M (adjusted 
to pH 7.20). 
Isolation of Peritoneal Elicited and Intravascular PAINs. Pathogen-free, male, outbred 
Long-Evans rats weighing 400-450 g were purchased from the Charles River Company (Bar Har- 
bor, Maine). For each experiment, five rats were injected intraperitoneally (under ether anesthesia) 
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with 30 ml of sterile 0.9 % NaC1 solution containing 1% (w/v) glycogen and then allowed to recover 
from anesthesia. Thereafter, at intervals of 1, 2, 3, 4, and 16 h following the injection, one rat 
was killed (by cardiac puncture under ether anesthesia), its peritoneal cavity opened, and the fluid 
therein collected and combined with two subsequent peritoneal washings using 0.9% NaC1 solu- 
tion. These elicited peritoneal cells were then pelleted, subjected to NH4C1 erythrocyte lysis, 
washed, and resuspended at 10 x 106 cells/ml in immunofluorescence wash buffer (21) at 4~ 
prior to staining with monoclonat reagents. Five milliliters of heparinized whole blood obtained 
from each rat at the time of cardiac puncture was subjected to NH~CI erythrocyte lysis (one part 
blood to eight parts NH4C1 buffer at 25~ for 5-10 minutes). The leukocytes were then washed 
twice with PBS and suspended in DPBS prior to in vitro stimulation. Each experiment also included 
a control animal (anesthetized but not injected with glycogen) from which blood was obtained at 
time 0, as described above. Total and differential leukocyte counts were determined morphologi- 
cally using Wright-Giemsa-stained intravascular and peritoneal specimens. Absolute PMN counts 
were calculated as the percentage of the total leukocyte count comprising segmented and band 
forms. 
Collection of Peritoneal Fluid Supernatant (PFS). Two rats were injected intraperitoneally 
with sterile 0.9% NaC1 solution containing 1% glycogen, as described above. After 4 h, approxi- 
mately 15 ml of intraperitoneal fluid were collected from each rat and subjected to high-speed 
centrifugation to pellet suspended cells. Aliquots of the resulting cell-free PFS were stored at -80~ 
until used for in vitro stimulation of isolated, intravascular PMNs. 
In Vitro Stimulation of PMNs. Isolated leukocytes harvested at each time point were sus- 
pended at 4-12 x 106/ml in DPBS and placed in polypropylene culture tubes (Falcon Plastics, 
Oxnard, California). Cells were then exposed to an equal volume of undiluted PFS and incubated 
at 37~ for 30 rain. Control cells received an equal volume of DPBS and were incubated for 30 
min at either 37~ or 4~ Cells were then diluted in ~ce-cold PBS, pelleted, and resuspended in 
immunofluorescence wash buffer (21) prior to further analysis. 
lmmunofluorescence Analysis. The generation and characterization of murine monoclonal 
antibodies anti-MoI (anti-CD1 lb, IgM; clone 17) (25) and anti-Mo2 (anti CD14, IgM; clone 116) 
(26) have been described. Mnrthe clone 17 anti-(human) Mol cross-reacts with the rat PMN hom- 
olog and inhibits rat PMN aggregation (Freyer and Todd, unpublished observations, August 1987). 
PMNs were subjected to indirect immunofluoreseence staining for the expression of the Mol 
(CD1 Ib) antigenic determinant relative to background staining by the isotype identical negative- 
control antibody, anti-Mo2 (anti-CD14), and examined by flow cytometric analysis as described 
(21, 27). For experiments shown in Table 2, specific fluorescence intensity represents the computed 
mean channel number (0-230 channels, linear scale) c~f cells stained with the anti-Mol reagent 
minus the mean channel number of ceJls stained with anti-Mo2 reagent. In Table 2 below, numbers 
in parentheses indicate the "-fold" increase in specific fluorescence intensity of either PFS-stim- 
ulated intravascular PMNs or elicited peritoneal PMNs, as compared to unstimulated intravascular 
PMNs maintained at 4~ The statistical significance of variations in the absolute PMN counts or 
in the stimulated increases in specific fluorescence intensity were evaluated by Student's t test. 
R E S U L T S  
In e x a m i n i n g  neut rophi l  r e sponses  to loca l ized  in f lammat ion  in the rat, we  
first m e a s u r e d  the n u m b e r  o f  P M N s  recrui ted to the per i toneal  cavity as a func-  
t ion o f  t ime ,  fo l lowing  the ins t i l la t ion o f  a local  in f lammatory  agent  [sterile 1% 
(w/v)  g l y c o g e n  solut ion] .  As  s h o w n  in Table  1, there  was  a p ro found  rise in 
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Table 1. Peritoneal, Not Intravascular, PMN Counts are Rapidly Increased in Response to Local- 
ized Inflammation ~ 
Absolute PMN counl J' 
Time (hs) Peritoneal (total) ]ntravascular (per ml) 
0 1.8 + 1.3 (26.8 • 9.5) ~ 
1 2.1 4- 1.0 (34.3 _+ 28,9) ~ 0.8 5:0.3 a (12.0 • 0.8) ~ 
2 12.2 ___ 9.1 (75.4 + 21.6) 2.8 _ 1.1 (31.0 5: 8.6) 
3 50.9 • 17.1 (98.2 4- 2,0) 2.7 + 0,8 (34.2 ___ 10.8) 
4 119.3 ___ 80.8 (98.4 -- 2.1) 2.1 ___ 1.2 (30.0 5: 9.7) 
16 212.0 • 76.3 (90.2 • 15.0) ~ 9.5 _+ 7.2 ~ (63.7 + 28.7)" 
"For each experiment (N = 5), five rats were injected intraperitoneally with 30 ml sterile 1% 
glycogen solution. Thereafter, at 1, 2, 3, 4, and 16 h following the injection, one rat was killed 
for the collection of accumulated peritoneal and intmvascular PMNs, as described in Materials 
and Methods. Each experiment also included a control animal (not injected with glycogen) from 
which blood was similarly obtained at time 0. For all peritoneal and intravascular specimens, total 
leukocyte counts were determined on cell suspensions examined in a standard hemacytometer, 
and differential leukocyte counts were determined morphologically using Wright-Giemsa stained 
slide preparations. 
bThe absolute PMN count (calculated as the percentage of the total leukocyte count comprising 
segmented and band forms) of peritoneal and intravascular specimens was determined for each 
time point. Peritoneal values are expressed as the mean total absolute PMN count • 106 i SD, 
and intravascular values as the mean absolute PMN count x 106 per milliliter of whole blood ! 
SD. For both, numbers in parentheses represent the mean percentage of PMNs _+ SD. 
~N= 4. 
Up = NS (as compared to intravascular PMN count at time 0). 
~N = 3. 
the mean  absolute  per i toneal  P M N  count  that was direct ly related to the durat ion 
o f  the inf lammatory  exposure .  Whereas  in normal  rats there were  negl ig ib le  
numbers  o f  resident  per i toneal  P M N s  ( t ime 0), af ter  1 and 16 h there were  mean  
total  per i toneal  P M N  counts  o f  2.1 and 212 .0  • 106, respect ive ly ,  s ignifying 
a 100-fold increase o v e r  this t ime  interval .  In  contrast ,  there was no signif icant  
var ia t ion  o v e r  t ime  in the  mean  int ravascular  P M N  count,  Addi t ional ly ,  as 
shown in Tab le  1, we  observed  that wi th in  2 - 3  h o f  intraperi toneal  g lycogen  
in jec t ion ,  o v e r  90% o f  the accumula ted  leukocytes  were  P M N s ,  whereas  the 
percen tage  o f  in t ravascular  P M N s  did not  vary  apprec iab ly  o v e r  t ime.  These  
results indicate  that  in this in v i v o  mode l  o f  loca l ized  ( intraperi toneal)  inf lam- 
mat ion ,  there was a rapid,  marked ,  and reproducible  accumula t ion  o f  P M N s  
that  was not  accompan ied  by changes  in the P M N  count  o f  the circulat ing,  
in t ravascular  l eukocyte  pool .  
To  assess  the re la t ive  state o f  ac t iva t ion  o f  rat P M N s  in the intravascular  
and per i toneal  compar tments ,  we e x a m i n e d  the surface express ion  o f  the 
CD1 t b / C D 1 8  ( M o l )  g lycopro te in ,  which  is an adhes ion-promot ing  mo lecu l e  
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w h o s e  densi ty  on the P M N  plasma membrane  is up-modula ted  by exposure  to 
in f lammatory  factors  ( t 0 )  and may  play a role  in the diapedesis  and directed 
migra t ion  o f  P M N s  responding  to an inf lammatory  st imulus.  In the immunof lu-  
o rescence  analysis  shown in Tab le  2, surface  M o t  express ion by isolated 
per i toneal  P M N s  was signif icantly increased as compared  to intravascular  P M N s  
kept  uns t imula ted  at 4 ~  This  increase in specific f luorescence  intensi ty (SFI)  
above  that  o f  uns t imula ted  in t ravascular  P M N s  isolated s imul taneously  ranged 
f rom 4 .3-  to 8 .6- fo ld  o v e r  the first 4 h (P  = NS,  < 0 . 0 1 ,  < 0 . 0 1 ,  and < 0 . 0 5 ,  
for  1, 2, 3, and 4 h, respect ive ly)  and was o f  lesser  magni tude  after 16 h. W e  
de tec ted  no s ignif icant  var ia t ion  o v e r  t ime  in the " b a s e l i n e "  SFI  o f  unst imu-  
lated in t ravascular  P M N s .  H o w e v e r ,  as shown in Tab le  2, these isolated intra- 
Table 2. Increased Surface Mol Expression is Detected on PMNs Isolated from Inflammatory 
Focus or Stimulated In Vitro" 
Specific fluorescence intensity b 
Intravascular PMNs Peritoneal PMNs 
Time (hs) 4~ PFS-stimulated 4~ 
0 1.8 + 1.3 8.9 • 5.6 ~ (4.9) 
1 3.4 _+ 1.8 I6.6 _+ 7.7 a (-,.9) t4.5 +_ 11.4 * (4.3) 
2 1.9 • 1.2 8.6 _+ 5.4I(4.5) 13.t • 6.4d (4.5) 
3 2.3 • 1.7 12.1 • 6.9/(5.3) 12.1 _+ 5.0~ (5.3) 
4 1.6 • 1.1 10.3 _+ 4.9d (6.4) 13.8 • 9.2I(8.6) 
16 5_5 _+ 5.1 ~ 15.0 • 10.4 (2.7) 8.6 _+ 5~3 (1.6) 
~Peritoneal and intravascular PMNs (N = 5) were coliected as described in Table 1, footnote a. 
Isolated peritoneal PMNs were maintained at 4~ whereas isolated intravascular PMNs were 
either kept at 4~ or exposed to cell-free peritoneal fluid supematant (PFS, prepared in Materials 
and Methods) at 37~ for 30 rain, PMNs were then stained by indirect immunofluorescence for 
the expression of the Mol (CD1 lb) determinant, relative to the background staining by an isotype- 
identical negative-control antibody. 
bValues represent the mean specific fluorescence intensity _+ SD (0-230 channels, linear scale) of 
cells stained by anti-Mol antibody; nonspecific background staining by the negative-control anti- 
body has been subtracted in each case. Photomultipl~er tube setting was 10130 mV in all experi- 
ments. Numbers in parentheses represent the -fold increase of specific fluorescence intensity of 
either peritoneal PMNs (4~ or intravascular PMNs exposed to PFS at 37~ for 30 rain, above 
that of intravascular PMNs maintained at 4"C. The corresponding relative increase in surface 
Mol expression stimulated by warming of intravascular PMNs in the absence of PFS was 2.7-, 
2.4-, 3.4-, 3.1-, 2.6-, and 2.3-fold at 0, 1, 2, 3, 4, and 16 h, respectively. 
cp = 0.05. 
gP < 0.01. 
~P = NS. 
~P < 0.05. 
SWhile there was a tendency for intrasvacular PMNs isolated at 16 h to exhibit higher than baseline 
(time 0) surface Mol expression (which could indicate delayed intmvascular PMN activation), 
the difference did not reach statistical significance (P = NS). 
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vascular PMNs, when exposed to peritoneal fluid supernatant (PFS) in vitro at 
37~ for 30 rain, could up-modulate their surface Mol antigen density to levels 
that approached or exceeded those of peritoneal PMNs isolated simultaneously. 
This stimulated enhancement of Mo 1 expression by PFS-exposed intravascular 
PMNs averaged 5.2-fold above that of circulating PMNs kept at 4~ (signifi- 
cant 0-4 h), with a lesser increase stimulated after 16 h. Isolated intravascular 
PMNs incubated in buffer alone at 37~ for 30 min (in the absence of PFS) 
exhibited an intermediate enhancement of Mol expression (Table 2, footnote 
b). Collectively, these results demonstrate that an increase in the surface expres- 
sion of the Mol adhesion glycoprotein is a feature characteristic of PMNs 
recruited from the intravascular leukocyte pool to sites of acute inflammation. 
DISCUSSION 
Since the accumulation of PMNs at sites of inflammation in vivo is depen- 
dent upon several adhesion-related processes (e.g., margination, diapedesis, 
and directed migration), in this study we sought to characterize the relationship 
between the inflammatory recruitment of PMNs and their surface expression of 
the adhesion-promoting plasma membrane glycoprotein, Mol. Mol (CDllb/  
CD 18; CR3; gp 155,95) is a member of the CD 11/CD 18 family of structurally 
related heterodimers expressed on the surfaces of PMNs and certain mononu- 
clear phagocytes (10) and has been shown to promote multiple cellular adhesive 
interactions, including PMN adherence and spreading on artificial (25, 28) and 
cellular (29, 30) substrates, aggregation (14, 28, 29), chemotaxis (25, 28), and 
binding of C3bi-opsonized particles (31-33) and gram-negative bacteria (34). 
The Mol glycoprotein exists in an intracellular pool associated with secondary 
and/or tertiary granules (16, 20, 35) and is rapidly translocated to the plasma 
membrane upon exposure of the cell to a variety of activating factors [e.g., 
FMLP (12, 13), C5a (14-16), LTB4 (17, 18), ATP (19), PMA and A23187 
(12, 20, 21), and others], thus serving as an "activation marker" for PMNs. 
We have found that PMNs accumulating at sites of acute inflammation in 
vivo do indeed significantly up-modulate their surface density of the Mol anti- 
gen, as compared to intravascular PMNs isolated simultaneously from the same 
animal. Moreover, we have shown that this enhancement occurs rapidly (within 
1 h of recruitment), is sustained with further local recruitment of PMNs, and is 
not accompanied by significant elevations of either the Mol expression or the 
total count of intravascular PMNs. Thus, our findings extend the observations 
of Zimmerli et al. (5), who reported a twofold increase in surface Mol expres- 
sion by exudative guinea pig and human PMNs analyzed at a single time point 
(14 h) following the introduction of an inflammatory stimulus. 
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Since Mol up-modulation coincided with PMN accumulation at the site of 
peritoneal inflammation, we evaluated the possibility that the administration of 
specific anti-Mol monoclonal antibody might interfere with this process. How- 
ever, when a simitar group of rats were pretreated (1 mg intravenously 1 h 
before glycogen injection) with a murine anti-human Mol antibody (clone 17 
producing an IgM antibody cross-reacting with the rat homolog), there was no 
significant reduction in intmperitoneal PMN accumulation 4 h after glycogen 
injection (despite the presence of saturating concentrations of anti-Mol anti- 
body in the plasma and peritoneal fluid), as compared to negative control rats 
receiving no antibody (113 _ 10 vs. 106 -L-_ 5 • 106, respectively; mean total 
peritoneal PMN count _+ SD, N = 3). This is in contrast to the findings of 
Rosen and Gordon (36), who recently reported a 75% inhibition of myelo- 
monocytic cell accumulation in a murine model of sterile peritonitis where mice 
were pretreated with an anti-Mol antibody. The discrepancy in these results is 
most likely due to a difference in epitope recognition in which one antibody but 
not the other competitively binds to a region of the Mol glycoprotein that pro- 
motes PMN adhesive interactions critical to inflammatory recruitment in vivo 
(25, 28, 29). The importance of the CDll/CD18 family of adhesion glycopro- 
teins in PMN migration to inflammatory loci has been indicated by the inhibi- 
tory effects of other CDll/CD18-specific monoclonal reagents in several 
additional animal models of acute inflammation (37-41). 
While some degree of surface Mol expression is required for normal PMN 
adhesive function in the inflammatory response, the functional importance of 
the increase in receptor density above baseline exhibited by activated cells is 
unclear. The physiologic significance of enhanced Mol expression is suggested 
by its detection in the settings of clinically active systemic lupus erythematosus 
(22), hemodialysis leukopenia (14), severe burns (23), and the treatment of 
cancer patients with intravenous GM-CSF (24). However, a series of recent 
observations suggest that qualitative, rather than quantitative, changes in exist- 
ing plasma membrane Mol receptors could underlie the enhanced cellular adhe- 
siveness observed in stimulated PMNs. Wright and coworkers reported the acti- 
vation and deactivation of CR3 (Mol) binding activity in human PMNs and 
monocytes without a corresponding change in receptor number (42, 43). More 
recently, Vedder and Harlan described increased adherence of human PMNs to 
cultured endothelial cell monolayers that was independent of the enhancement 
of CDI tb  or CD18 determinants detected on PMNs stimulated by PMA, 
A23187, or FMLP (44). In addition, Buyon et al. reported that maximal FMLP- 
stimulated aggregation of human PMNs did not correspond to increases in sur- 
face Mol expression (45). Examples of qualitative changes in the Mol receptor 
that might confer functional responsiveness include topographic clustering of 
CR3 receptors on the plasma membrane (46, 47) or glycoprotein phosphoryla- 
tion (43, 48). Thus, the well-documented inhibitory effect of certain anti-Mol 
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m o n o c l o n a l  r eagen t s  o n  the  r e c r u i t m e n t  o f  P M N s  to i n f l a m m a t o r y  loc i  in v ivo  
( 3 6 - 4 1 )  cou ld  b e  due  to  an  i n t e r f e r ence  w i th  such  qua l i t a t ive  changes .  I f  t rue ,  
t he  e n h a n c e m e n t  o f  M o l  e x p r e s s i o n  by  P M N s  rec ru i t ed  dur ing  i n f l a m m a t i o n ,  
as r epo r t ed  here ,  m a y  se rve  a pu r pos e  ye t  to b e  e luc ida ted .  
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